Planning Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Planning Strategies's FDMT Position: Q3 2026 in Review
Planning Strategies held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 502 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #383.
Planning Strategies first reported a position in FDMT in Q2 2026 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Planning Strategies held 502 shares of 4D Molecular Therapeutics worth $7.18K as of Q3 2026.
- Planning Strategies left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
- 4D Molecular Therapeutics made up ﹤0.01% of Planning Strategies's portfolio in Q3 2026, its #383 holding.
- Planning Strategies first reported a position in 4D Molecular Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 166 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Planning Strategies's 13F filing for Q3 2026, filed 2 Oct 2026.